Atlas One · Host Biology · Scale 03 — Molecular

FLT3

Receptor tyrosine kinase mutated in ~25-30% of AML (ITD tandem duplications in JM domain and TKD point mutations); constitutive kinase → STAT5, ERK, PI3K → blast proliferation and survival. Midostaurin (frontline) and gilteritinib (relapsed) are approved FLT3 inhibitors in AML.

Also known as: FLT3, FMS-like tyrosine kinase 3, CD135, STK1, FLK2, FLT3-ITD, FLT3-TKD, FLT3 internal tandem duplication

Scale 03 — MolecularScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
flt3

FLT3

Receptor tyrosine kinase mutated in ~25-30% of AML (ITD tandem duplications in JM domain and TKD point mutations); constitutive kinase → STAT5, ERK, PI3K → blast proliferation and survival. Midostaurin (frontline) and gilteritinib (relapsed) are approved FLT3 inhibitors in AML.

Entry Metadata

FieldValue
IDflt3
NameFLT3
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale03-molecular

Cross-Atlas Connections

connects-toStat3 connects-toMyc connects-toMtor connects-toKras connects-toNpm1 connects-toDnmt3A connects-toBcl 2

Sources